The total return over the past 12 months is +9.50% vs. +16.94% for the S&P 500. So far it's up -51.07% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +9.50% | +5.22% | (44.39%) | (29.11%) | N/A | N/A |
| Total Return CAGR | +9.50% | +5.22% | (44.39%) | (29.11%) | N/A | N/A |
| Revenue CAGR | (60.77%) | +14.89% | +27.24% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Insight Molecular Diagnostics Inc. (IMDX)
| Year | Start price | End price | IMDX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $7.50 | $3.67 | (51.07%) | +14.51% | (65.58%) |
| 2025 | $2.38 | $7.50 | +215.13% | +17.72% | +197.41% |
| 2024 | $2.50 | $2.38 | (4.80%) | +24.89% | (29.69%) |
| 2023 | $6.42 | $2.50 | (61.06%) | +26.19% | (87.25%) |
| 2022 | $43.40 | $6.42 | (85.21%) | (18.17%) | (67.04%) |
| 2021 | $47.80 | $43.40 | (9.21%) | +28.74% | (37.95%) |
| 2020 | $45.00 | $47.80 | +6.22% | +18.37% | (12.15%) |
| 2019 | $27.60 | $45.00 | +63.04% | +31.22% | +31.82% |
| 2018 | $93.00 | $27.60 | (70.32%) | (4.56%) | (65.76%) |
| 2017 | $141.00 | $93.00 | (34.04%) | +21.70% | (55.74%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
